Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Wisconsin

Release Date: November 6, 2025

Expiration Date: December 11, 2025

Activity Overview

DLL3-targeted agents—including bispecific antibodies, antibody-drug conjugates (ADCs), and chimeric antigen (CAR) T-cell therapies—are reshaping the treatment landscape for extensive-stage small cell lung cancer (ES-SCLC). These advances bring new hope to patients who historically have had limited options. As these therapies become available, clinicians must stay current on their clinical efficacy and unique associated adverse events, such as cytokine release syndrome and immune cell–associated neurotoxicity syndrome.

This program brings together expert faculty to discuss the latest advances and enable the integration of these novel DLL3-targeted agents into ES-SCLC care. Through interactive, case-based discussions with a community oncology colleague, participants will gain practical insights and strategies to navigate emerging efficacy data, anticipate and manage therapy-related toxicities, and address the evolving challenges of patient care in this setting.

This educational activity is an archive of the Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice presentation held on October 28, 2025.

Target Audience

This educational program is primarily directed toward community-based oncologists and other health care providers involved in the treatment of SCLC.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe the rationale and mechanism of actions for emerging DLL3-targeted agents, including bispecific antibodies, ADCs, and CAR T-cell therapies
• Evaluate the latest trial data on DLL3-targeting therapies in SCLC
• Implement care plans to monitor and mitigate common adverse effects of DLL3-targeted therapies using evidence-based management approaches
• Apply strategies to effectively coordinate care between the community cancer and academic centers

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC (PER^®) have no relevant financial relationships with ineligible companies.

PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.